secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2022-10-03T23:59:59+00:00
Accession:  0001493152-22-027459
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon appoints Curis CEO James E. Dentzer to board effective Sept 29, 2022
---------------------------------------------------------------------------

- James E. Dentzer appointed as Class II director; board expands to nine members.
- Dentzer is President & CEO of Curis, Inc., with over 20 years of biopharma financial leadership.
- Receives standard non-employee director compensation plus initial option grant for 2,667 shares vesting over three years.
- Board determined Dentzer is independent under SEC and NASDAQ rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315222027459/0001493152-22-027459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315222027459/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-027459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer